FDA’s ‘Imminent Action’ Policy Likely Not Best Path For ANDAs To Address Late Brand Label Changes

 
• By Derrick Gingery
  
Drug warning label
Multiple FDA policies could help generic sponsors avoid approval delays caused by late RLD labeling changes. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics